Abstract
Alcohol represents the oldest substance of abuse known and Alcoholic Liver Disease (ALD) is the most common cause of chronic liver disease worldwide. The ALD includes a wide spectrum of injury and may lead progressively from simple steatosis to frank cirrhosis. The ALD diagnosis may be hard and it is mainly defined by the history of chronic alcohol intake, physical and laboratory abnormalities suggestive of liver disease. Abstinence is the cornerstone of ALD therapy. Although the burden on health of ALD is not negligible, in the last decades few therapeutic advances have been made. Because of the complex pathogenetic mechanisms, the therapy of ALD and especially of severe Alcoholic Hepatitis (AH), represents a thorny problem in the clinical practice. In severe forms of acute AH, some specific drug treatments, including glucorticoids or pentoxifylline, have been defined and are, at the moment, recommended by international guidelines. On the contrary, specific long-term treatments of ALD, aimed at stopping the progression of fibrosis, are not yet approved.
Keywords: Abstinence, acetaldehyde, alcohol, alcoholic hepatitis, alcoholic liver disease, cirrhosis, fibrosis, endoscopy, gastropathy.
Reviews on Recent Clinical Trials
Title:Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment
Volume: 11 Issue: 3
Author(s): Ludovico Abenavoli, Mario Masarone, Alessandro Federico, Valerio Rosato, Marcello Dallio, Carmela Loguercio and Marcello Persico
Affiliation:
Keywords: Abstinence, acetaldehyde, alcohol, alcoholic hepatitis, alcoholic liver disease, cirrhosis, fibrosis, endoscopy, gastropathy.
Abstract: Alcohol represents the oldest substance of abuse known and Alcoholic Liver Disease (ALD) is the most common cause of chronic liver disease worldwide. The ALD includes a wide spectrum of injury and may lead progressively from simple steatosis to frank cirrhosis. The ALD diagnosis may be hard and it is mainly defined by the history of chronic alcohol intake, physical and laboratory abnormalities suggestive of liver disease. Abstinence is the cornerstone of ALD therapy. Although the burden on health of ALD is not negligible, in the last decades few therapeutic advances have been made. Because of the complex pathogenetic mechanisms, the therapy of ALD and especially of severe Alcoholic Hepatitis (AH), represents a thorny problem in the clinical practice. In severe forms of acute AH, some specific drug treatments, including glucorticoids or pentoxifylline, have been defined and are, at the moment, recommended by international guidelines. On the contrary, specific long-term treatments of ALD, aimed at stopping the progression of fibrosis, are not yet approved.
Export Options
About this article
Cite this article as:
Abenavoli Ludovico, Masarone Mario, Federico Alessandro, Rosato Valerio, Dallio Marcello, Loguercio Carmela and Persico Marcello, Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment, Reviews on Recent Clinical Trials 2016; 11 (3) . https://dx.doi.org/10.2174/1574887111666160724183409
DOI https://dx.doi.org/10.2174/1574887111666160724183409 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy
Current Vascular Pharmacology Non-uremic Calciphylaxis: A Rare and Late Adverse Reaction of Warfarin
Current Drug Safety Interstitial Lung Disease in Rheumatoid Arthritis
Current Rheumatology Reviews Reactive Oxygen Species: Physiological Roles in the Regulation of Vascular Cells
Current Molecular Medicine The Role of SPECT and MRI for Pre and Postoperative Evaluation of Childhood Moyamoya Disease: Case Report and Review of Literature
Current Medical Imaging Comprehensive in silico Study of GLUT10: Prediction of Possible Substrate Binding Sites and Interacting Molecules
Current Pharmaceutical Biotechnology Why Does Obesity Increase the Risk for Cardiovascular Disease?
Current Pharmaceutical Design Modulation of Angiotensin II Effects, A Potential Novel Approach to Inflammatory and Immune Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Current Alzheimer Research Meet Our Editorial Board Member
Current Bioactive Compounds Treatment of Hypertension Induced Albuminuria
Current Pharmaceutical Design Acute Gout: The Inflammasome
Current Rheumatology Reviews A Case of Heavy Proteinuric Non-IgA Mesangial Proliferative Glomerulonephritis Ameliorated by Chinese Herbal Medicines
Current Traditional Medicine An Update on Disease Modifying Antirheumatic Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan
Current Drug Safety Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Lifestyle Modification for Masked Hypertension
Current Hypertension Reviews Human Inter-Individual DNA Sequence Variation in Candidate Genes, Drug Targets, the Importance of Haplotypes and Pharmacogenomics
Current Pharmaceutical Biotechnology Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery